Oramed Pharmaceuticals (ORMP) Change in Cash (2010 - 2026)

Oramed Pharmaceuticals has reported Change in Cash for 17 years, with the latest figure at -$32.7 million in Q1 2026.

• For the quarter ending Q1 2026, Change in Cash fell 262.94% year-over-year to -$32.7 million; the trailing twelve-month figure through Mar 2026 stood at -$61.3 million (down 209.61% YoY), and the FY2025 full-year result was -$8.5 million, down 118.68% from the prior year.
• Change in Cash for Q1 2026 stood at -$32.7 million, down from -$6.2 million in the prior quarter.
• The five-year high for Change in Cash was $66.2 million in Q2 2024, with the low at -$58.7 million in Q2 2025.
• Historically, Change in Cash has averaged -$838470.6 across 5 years, with a median of $1.9 million in 2022.
• Annual changes were most pronounced in 2023 — Change in Cash slumped 3301.57% — and 2024, when it soared 481.71%.
• Oramed Pharmaceuticals' Change in Cash stood at $7.3 million in 2022, then slumped by 50.65% to $3.6 million in 2023, then jumped by 243.35% to $12.3 million in 2024, then slumped by 150.6% to -$6.2 million in 2025, then sank by 425.43% to -$32.7 million in 2026.
• The last three Change in Cash figures came in at -$32.7 million (Q1 2026), -$6.2 million (Q4 2025), and $36.4 million (Q3 2025), per Business Quant data.